

Current as of August 25, 2025 Short talks selected from proffered abstracts

PR-01 **Targeting the ApoE-LDLR Pathway Disrupts MDSC-Mediated Systemic Immunosuppression and Enhances the Efficacy of NK Cell Immunotherapy** Chunbo He Affiliated Provincial Hospital of Fuzhou University, Fuzhou University, Fuzhou, Taiwan (Greater China)

PR-02 **Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance** Katie Owen Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

PR-03 **Tumor-derived Complement Factor B drives tumor growth and anti-PD-1 resistance in STK11 -mutant lung adenocarcinoma** Edwin Yau Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States

PR-04 **Targeting PRMT5 to modulate endogenous retroviruses expression in melanoma** Simon Milette Yale University, New Haven, CT, United States

PR-05 **Sumoylation blockade exposes the dark epigenome to drive ZBP1 viral mimicry for cancer immunotherapy** Maria Goicoechea The Institute of Cancer Research, London, United Kingdom

PR-06 **Disrupting TACI signalling to restore immune balance: harnessing translational opportunities at the intersection of cancer and autoimmunity** Yong Sheng QIMR Medical Research Institution, Brisbane, QLD, Australia

PR-07 **Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice** Camille Hansen University of Utah, Salt Lake City, UT, United States

PR-08 **Impact of gut microbiota on response to Bacillus Calmette-Guérin immunotherapy in bladder cancer: Towards a predictive molecular model** Marine Boireau Faculty of Medicine, Université Laval, Québec, QC, Canada

PR-09 **Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)** Zeynep Kosaloglu-Yalcin La Jolla Institute for Immunology, La Jolla, CA, United States

PR-10 **Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade** Kristen Pauken The University of Texas MD Anderson Cancer Center, Houston, TX, United States

PR-11 **B cell infiltration and clonal expansion in tertiary lymphoid structures: insights from intravital microscopy** Gabrielle Rowe-Brown Johns Hopkins All Children's Hospital, Saint Petersburg, FL, United States

PR-12 **Single-cell profiling of tumor-infiltrating B cells reveals autoantibody repertoires and potential cross-talk with T cells** Mikiya Takata The University of Tokyo, Tokyo, Japan

PR-13 **Myeloid checkpoint blockade Potentiates Radiotherapy by Modulating Dendritic Cells and Reducing Treg-Driven Immunosuppression** Maud Charpentier Weill Cornell Medical College, New York, NY, United States

PR-14 **Unraveling the Sexually Dimorphic Immune Microenvironment in Gastric Cancer** Ryan Heslin University of Texas Southwestern Medical Center, Dallas, TX, United States

PR-15 **Neuroimmune dysregulation in ovarian cancer: the role of chronic stress on microglial activation and systemic inflammation.** Luinet Melendez-Rodriguez Ponce Health Sciences University, Coto Laurel, United States

PR-16 **Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity** Cong Xing UT Southwestern Medical Center, Dallas, TX, United States

Poster Session A (September 25, 2025, 6-8 p.m.)

A001 **nELISA high-throughput protein profiling applied to the RADIOHEAD cohort: insights from the largest plasma proteomics study of patients receiving checkpoint inhibitor therapy** Eric Miller Nomic Bio, Montreal, QC, Canada

A002 **Comprehensive blood profiling for immunotherapy outcome prediction and longitudinal immune trajectory characterisation** Max Emmerich The Francis Crick Institute, London, United Kingdom

A003 **Identification of immunomodulatory compounds by high-throughput proteomics: Insights from quantification of 1000 proteins in a 20,000 sample screen** Nathaniel Robichaud Nomic Bio, Montreal, QC, Canada

PR-04 **Targeting PRMT5 to modulate endogenous retroviruses expression in melanoma** Simon Milette Yale University, New Haven, CT, United States

A004 **Modulating chromatin remodeling as a strategy to reverse immune evasion in ovarian cancer** Olivia Mckeeman Lady Davis Institute for Medical Research, MONTREAL, QC, Canada

A005 **TAZ-TEAD signaling alters the immune microenvironment of cutaneous melanoma** Kristen DeRosa Thomas Jefferson University, Philadelphia, PA, United States

A006 **Assessment of EBV DNA methylation to guide antiviral use in EBV-associated lymphoma** Cara Noel Ohio State University, Columbus, OH, United States

A007 **Radiomics of anaplastic Wilms tumors: Unraveling oncogenic-Immune dynamics** Xiaoping Su MD Anderson Cancer Center, Houston, TX, United States

A008 **RELATIONSHIP BETWEEN CD4$^+$ T CELLS AND CANCER STEM CELLS IN SQUAMOUS CANCERS OF THE ORO-ESOPHAGEAL TRACT** Maxence Plateau University of Sherbrooke, Sherbrooke, QC, Canada

A009 **Novel roles of the nuclear autoantigen LEDGF/p75 in modulating prostate cancer related inflammatory pathways and cancer patient response to immunotherapy** Carlos Casiano Loma Linda University, Loma Linda, CA, United States

A010PR-11 **B cell infiltration and clonal expansion in tertiary lymphoid structures: insights from intravital microscopy** Gabrielle Rowe-Brown Johns Hopkins All Children's Hospital, Saint Petersburg, FL, United States

A011PR-03 **Tumor-derived Complement Factor B drives tumor growth and anti-PD-1 resistance in STK11 -mutant lung adenocarcinoma** Edwin Yau Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States

A012 **Cancer acquires therapy resistance by converting immune infiltration to exclusion through NK cell-macrophage interactions** Andrew White Cornell University, Ithaca, NY, United States

A013 **Fibroblast activation protein (FAP) enhances adoptive NK cell therapy in solid tumors** Marwa Afifi Georgetown University, Washington, DC, United States

A014 **Chronic stress impairs anti-tumor immunity in ovarian cancer via MDSCs and notch pathway activation** Yadiel Rivera-Lopez Ponce Health Sciences University, Ponce, Puerto Rico

A015 **The Emerging Role of Basophils in Non-Muscle-Invasive Bladder Cancer** Geneviève Trépanire Université Laval, Québec, QC, Canada

A016 **KRASG12D inhibition enhances tumor cell sensitivity to natural killer cell-mediated cytotoxicity** Chunbo He Affiliated Provincial Hospital of Fuzhou University, Fuzhou, Taiwan (Greater China)

A017 **Neutrophil extracellular traps reprogram macrophages to an immunosuppressive phenotype in non-small-cell lung cancer** Simrit Safarulla McGill University, Montreal, QC, Canada

A018 **Targeting PTPN1/PTPN2 with KQ-791 Enhances NK Cell Cytotoxicity During Tumor Rechallenge** Sonali Uttam McGill University, Montreal, QC, Canada

A019 **Timed intracranial therapy with NK cells and NK cell-derived extracellular vesicles following temozolomide exhibits curative potential in mesenchymal glioblastoma model** Brian Meehan Research Institute of the McGill University Health Center, Montreal, QC, Canada

A020 **TLR10 as a Key Innate Immune Effector Regulating Metabolic and Redox Homeostasis in Head and Neck Squamous Cell Carcinoma** Bokyung Joo Kyungpook National University, daegu, Korea, Republic of

PR-02 **Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance** Katie Owen Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

A021PR-05 **Sumoylation blockade exposes the dark epigenome to drive ZBP1 viral mimicry for cancer immunotherapy** Maria Goicoechea The Institute of Cancer Research, London, United Kingdom

A022PR-16 **Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity** Cong Xing UT Southwestern Medical Center, Dallas, TX, United States

A023PR-13 **Myeloid checkpoint blockade Potentiates Radiotherapy by Modulating Dendritic Cells and Reducing Treg-Driven Immunosuppression** Maud Charpentier Weill Cornell Medical College, New York, NY, United States

Poster Session B (September 26, 2025, 6:30-8:30 p.m.)

B001PR-10 **Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade** Kristen Pauken The University of Texas MD Anderson Cancer Center, Houston, TX, United States

B002PR-09 **Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)** Zeynep Kosaloglu-Yalcin La Jolla Institute for Immunology, La Jolla, CA, United States

B003 **Oncolytic VSVd51-LIGHT and folfIrinox chemotherapy increases anti-tumor immune response in pancreatic ductal adenocarcinoma** Jacob Leger Université de Sherbrooke, Sherbrooke, QC, Canada

B004 **Route dependent T-cell activation by mRNA cluster therapies** Yodarlynis Campaneria University of Florida, Gainesville, FL, United States

B005 **Tumor-derived extracellular vesicles induce intrinsic apoptosis of activated T cells by early transcriptional activation of cellular stress response genes.** Theresa Whiteside University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA, United States

PR-12 **Single-cell profiling of tumor-infiltrating B cells reveals autoantibody repertoires and potential cross-talk with T cells** Mikiya Takata The University of Tokyo, Tokyo, Japan

B006PR-07 **Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice** Camille Hansen University of Utah, Salt Lake City, UT, United States

B007 **Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy** Maud Charpentier Weill Cornell Medical College, New York, NY, United States

B008PR-14 **Unraveling the Sexually Dimorphic Immune Microenvironment in Gastric Cancer** Ryan Heslin University of Texas Southwestern Medical Center, Dallas, TX, United States

B009 **Targeting PAR-2 improves tumor antigen presentation and primes the immune system for anti-PD-1 immunotherapy** Samya Aouad CRCHUM, Montreal, QC, Canada

PR-15 **Neuroimmune dysregulation in ovarian cancer: the role of chronic stress on microglial activation and systemic inflammation.** Luinet Melendez-Rodriguez Ponce Health Sciences University, Coto Laurel, United States

B010 **α-Synuclein preformed fibrils suppress cell cycle progression and glycolytic flux in glioblastoma cells** Hyo-Jin Song Kyungpook National University, Daegu, United States

B011 **Mast cells mediate tumor-suppressive effects in head and neck cancer through immune-microenvironmental regulation** Ching-Chuan Kuo National Health Research Institutes, Zhunan, Miaoli, Taiwan (Greater China)

B012 **Bromodomain and Extra-Terminal Domain (BET) as a Therapeutic Target in a Mouse Model of Secondary Hemophagocytic Lymphohistiocytosis (HLH)** Paola Marra The Ohio State University, Columbus, OH, United States

B013 **Evaluating Chi3L1 as a Potential Target for Immunotherapy in Chordoma** Margot Martinez-Moreno Brown University/Rhode Island Hospital, PROVIDENCE, RI, United States

B014 **SYNCRIP drives therapy resistance via ferroptosis suppression and metabolic activation in Glioblastoma.** Hyeon Ji Kim Kyungpook National University, Daegu, United States

B015 **3D Organoid-Based Therapeutics with Translational Potential in Cancer Immunity and Autoimmune Risk Prediction** SDANISH KADIR University of Texas Rio Grande Valley, Edinburg, TX, United States

B016 **Evaluation of the anti-breast cancer activity of isolates and semi-synthesized compounds from Alstonia scholaris leaves and Psorospermum guineense twigs** Ghansenyuy Salome Yuwong University of Yaounde 1, Yaounde, United States

B017PR-08 **Impact of gut microbiota on response to Bacillus Calmette-Guérin immunotherapy in bladder cancer: Towards a predictive molecular model** Marine Boireau Faculty of Medicine, Université Laval, Québec, QC, Canada

B018 **Gut microbiome influences the antitumor response to BCG immunotherapy in bladder cancer** Jalal Laaraj Cancer Research Center of Université Laval, Québec, QC, Canada

PR-06 **Disrupting TACI signalling to restore immune balance: harnessing translational opportunities at the intersection of cancer and autoimmunity** Yong Sheng QIMR Medical Research Institution, Brisbane, QLD, Australia

B019 **CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC.** Richard Pestell Pennsylvania Cancer and Regenerative Medicine Center, Baruch S. Blumberg Institute, Wynnewood, PA, United States

B020 **NETosis-specific clipped histone H3 is a novel biomarker of response to neoadjuvant chemo-immunotherapy in resectable lung cancer.** Muhammad Shahzad McGill University, Montreal, QC, Canada

B021 **Multi-functional telodendrimer nanodrug: Nanocarrier for ovarian cancer treatment and immunomodulator to control inflammation and sensitize the tumor** Hadil Gadelrab SUNY Upstate Medical University, Syracuse, NY, United States

B022 **Investigating Biased GPCRs Activation by Nutraceutical Caffeine and Nicotine in Transactivating Glycosylated Receptors to Induce EMT in Cancer Metastasis** Yunfan Li Queen's University, kingston, ON, Canada

B023 **A scalable, proteome-wide protein profiling platform with absolute quantification of 1000 proteins** Narges Rashidi Nomic, Montreal, QC, Canada

B024 **Tumor Resection Status Modulates Cardiometabolic Response to Imatinib in GIST** Allen Seylani Cleveland Clinic, Cleveland, OH, United States

B025 **An agentic platform for designing cancer immunotherapies: From automated variant interpretation to in silico therapeutic validation** Fahad Kiani CrisPRO.ai, Brooklyn, United States

B026PR-01 **Targeting the ApoE-LDLR Pathway Disrupts MDSC-Mediated Systemic Immunosuppression and Enhances the Efficacy of NK Cell Immunotherapy** Chunbo He Affiliated Provincial Hospital of Fuzhou University, Fuzhou University, Fuzhou, Taiwan (Greater China)

B027 **iSIGN panel identifies germ cell tumors via whole-proteome phage immunoprecipitation sequencing** M Bakri Hammami H. Lee Moffitt Cancer Center, Tampa, FL, United States